Internet Stroke Center Home Stroke Trials Registry
 
National Institute of Neurological Disorders & Stroke
American Stroke Association
Washington University School of Medicine
 
 Trials Directories
Ongoing Trials
Completed Trials
Acute Stroke Trials
Hemorrhage Trials
Prevention Trials
Recovery Trials
 Interventions
Drugs - By Name
Drugs - By Category
Procedures
Recovery Therapies
 Assessment Scales
Specific Stroke Scales
Stroke Scales Overview
 Stroke Trial Links
Government Sites
Independent Sites
 News & Updates
Update List
General Stroke News
About this Site
Submit Your Trial
Send Feedback

 Search for Trials

PubMed
We comply with the "Health on the Net" (HON) code of standards for trustworthy health information: verify here.



 
Stroke Interventions in Clinical Trials
Printable Version
SENTIS
Safety and Efficacy of NeuroFlo™ Technology in Ischemic Stroke



Principal Investigator
Ashfaq Shuaib, MD

PI Address
University of Alberta
Edmonton, Alberta T6G 2B7

Contact Address
Lori Austin, VP, Clinical Affairs
CoAxia, Inc.
10900 73rd Ave. N., Suite 102
Maple Grove, MN 55369

Ph: (763) 315-8380
Email: laustin@coaxia.com

OR

Keisha R. Sandberg, MPH
Sr. Clinical Research Associate
CoAxia, Inc.
10900 73rd Ave. N., Ste. 102
Maple Grove, MN 55369

Ph: (763) 315-8382
Fx: (763) 315-3660

Email: ksandberg@coaxia.com

Contact Email
info@coaxia.com

Sponsor



Trial Phase:Phase III
Study Size Actual:454
Study Size Planned:500
Centers Actual:72
Centers Planned:80
Max Time from onset:14 Hours
Min Age:18
Follow-up Duration:90 Days
ISRCTN#NCT00119717
Status:
Ongoing. As of October 1, 2009, 454 patients have been enrolled. Enrollment will continue through early 2010.

Purpose:
To determine if a unique method for increasing blood flow to the brain (with a catheter partially occluding the aorta) can minimize the damage caused by stroke and improve patient outcome.

Interventions:
Catheter
NeuroFlo catheter

Location(s):
U.S., Canada, Europe, and Israel.

Year Started: 2005

Design:
Prospective, controlled, randomized, single-blind, multicenter trial of NeuroFlo™ treatment plus standard medical management versus standard medical management alone.

Inclusion Criteria
Patients diagnosed with a focal neurological deficit due to ischemia, NIHSS 5-18, who can be treated within 14 hours of symptom onset.

Exclusion Criteria
Patients with hemorrhagic stroke, certain types of heart disease, kidney disease, and other conditions to be assessed by the study doctor.

Patient Involvement:
Participation in the study will last 90 days and involve 2 follow-up visits. Procedures include physical exams, lab work, neurological exams, CT/MR imaging, ECG. The treatment group will also receive an aortogram and NeuroFlo therapy.

Primary Outcome:
Efficacy as measured by neurological improvement; and safety as measured by serious adverse events at 90 days.

Secondary Outcome:
Acute improvement in neurological function 24 hours post-procedure, and comparison of SIS at 30 & 90 days, hospital length of stay, and patient disposition upon discharge.

Comments:
Scientific Name: SENTIS: A Multi-center Randomized Trial Evaluating Cerebral Perfusion Augmentation Via Partial
Aortic Occlusion In Acute Ischemic Stroke

Source of Information:
Correspondence with trial sponsor [July 2005].
Presented at the 2006 International Stroke Conference [February 2006].
Correspondence with trial sponsor [March 2006].
Correspondence with trial sponsor [July 2006].
Updated per correspondence with coordinator 11/4/08-jh.
Presented at the 2007 International Stroke Conference [February 2007].
Presented at the 2008 International Stroke Conference [February 2008].
Presented at the 2009 International Stroke Conference [February 2009].

Web Links and Publications:
CoAxia, INC.

SENTIS
ClinicalTrials.gov

This information last updated on: 10/5/2009

Reviewed on: 10/05/2009.

UID: 618

   

Internet Stroke Center at Washington University:
HOME | ABOUT | PRIVACY POLICY | CONTACT

Copyright © 1997-2009 - Internet Stroke Center. All rights reserved.                                           Last modified: Friday, November 20, 2009